DCM
TENX icon

DAFNA Capital Management’s Tenax Therapeutics TENX Stock Holding History

DAFNA Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$204K – 91
2016
Q2 		$204K Hold
2
– – 0.16% 78
2016
Q1 		$163K Hold
2
– – 0.14% 80
2015
Q4 		$261K Sell
2
-1
-33% -$104K 0.23% 63
2015
Q3 		$245K Buy
+3
New +$343K 0.24% 67

Other funds holding TENX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

DAFNA Capital Management's TENX Position: Q3 2016 in Review

DAFNA Capital Management sold out of Tenax Therapeutics (TENX) in Q3 2016, closing a stake of 2 shares — an estimated $204K sold.

DAFNA Capital Management first reported a position in TENX in Q3 2015 and held it in 4 quarters. The position peaked at $261K in Q4 2015. 23 funds tracked by Wall St. Rank hold TENX as of Q3 2016.

  • DAFNA Capital Management reported no remaining Tenax Therapeutics position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 2 Tenax Therapeutics shares in Q3 2016, an estimated $204K.
  • DAFNA Capital Management first reported a position in Tenax Therapeutics in Q3 2015 and held it in 4 quarters.
  • DAFNA Capital Management's Tenax Therapeutics position peaked at $261K in Q4 2015.
  • 23 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.